An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms

NCT ID: NCT02057497

Last Updated: 2017-10-20

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-10-09
• Study Completion Date: 2017-10-10

Brief Summary

G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions. In addition, G proteins binding to GPCRs either directly or permissively determine the efficacy of lifestyle interventions and drugs aiming at weight management and diabetes treatment. Polymor-phisms of the fat mass and obesity-related protein (FTO) gene have been also well characterised and linked to energy intake, body fat mass as well as CVD risk and the susceptibility to weight-reducing interventions. Stratifying patients according to G protein and FTO-related genotyping may enable a more accurate prediction of individual disease courses and responses to therapeutic interventions in terms of safety and tolerability as well as efficacy. Although the objectives primarily refer to the analysis of G pro-tein and FTO-related genotypes, also other genes of potential relevance for the evolution of obesity and/ or diabetes and the response to lifestyle and pharmacological interventions may be analysed.

Conditions

Prediabetes; Diabetes Type 1; Diabetes Type 2

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Healthy volunteers

Considered generally healthy based on medical history and physical examination as per discretion of the investigator

No interventions assigned to this group

Type 1 Diabetes

T1DM diagnosed clinically prior to start of trial examinations

No interventions assigned to this group

Type 2 Diabetes

T2DM diagnosis prior to the start of trial examinations

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

General

1. Informed consent obtained before any trial-related activities

2. Males and females equal or more than 18 years old Healthy volunteer-specific

3. Considered generally healthy based on medical history and physical examination as per discretion of the investigator

T2DM-specific

4. T2DM diagnosis prior to the start of trial examinations.

T1DM-specific

5. T1DM diagnosed clinically prior to start of trial examinations

Exclusion Criteria

General

1. Mental incapacity or language barriers which preclude adequate understanding or cooperation, unwillingness to participate in the trial, known or suspected not to comply with trial directives or not to be reliable or trustworthy, or subjects who in the opinion of their general practitioner or the Investigator should not participate in the trial.

Healthy volunteer-specific

2. Previous diagnosis of any type of diabetes mellitus, e.g. T1DM, T2DM, gestational diabetes, maturity onset diabetes of the young, etc.

T2DM-specific

3. T1DM, diabetes resulting from pancreatic injury, or secondary forms of diabetes, e.g., acrome-galy or Cushing's syndrome.

T1DM-specific

4. T2DM, diabetes resulting from pancreatic injury, or secondary forms of diabetes, e.g., acrome-galy or Cushing's syndrome.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Leona Plum-Mörschel, MD

Role: PRINCIPAL_INVESTIGATOR

Profil Institut fuer Stoffwechselforschung GmbH

Countries

Germany

Other Identifiers

OBDM-02

Identifier Type: -

Identifier Source: org_study_id